Investor Presentation Q1 2023
129
Investor presentation
First three months of 2023
Total RybelsusⓇ TRx volume is steadily growing in the US
RybelsusⓇ and SGLT-2i¹ uptake in the US² since respective launches
TRX count
(000s)
100
80
60
60
40
40
20
Rybelsus® TRX
SGLT-2i TRX
0
0
30
60
три
90
Time since launch (weeks)
89
NAO
•
•
In the first three months of 2023, RybelsusⓇ sales
account for 14% share of growth of NAO sales
Successful RybelsusⓇ launch despite COVID-19
impacting the first year of launch
RybelsusⓇ TRX continues to steadily increase
Achieved global blockbuster status in 2022
82
.
120
150
180
1SGLT-2i is an average of empagliflozin and canagliflozin script count. 2RybelsusⓇ is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: TRx: Total prescription data; NAO: North America Operations; Source: IQVIA Xponent, Week ending 14 April 2023View entire presentation